Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysine-specific histone demethylase 5B (KDM5B), also known as JARID1B or PLU-1, is a chromatin-modifying enzyme that specifically demethylates tri-, di-, and mono-methylated lysine 4 on histone H3 (H3K4) via an oxidative reaction requiring Fe²⁺ and α-ketoglutarate as cofactors[1][7][9]. KDM5B contains a catalytic jumonji C (JmjC) domain, an ARID DNA-binding domain, plant homeodomain fingers, and a zinc-finger motif, reflecting its multifaceted role in interpreting and modifying chromatin states[1][5]. By removing H3K4 methylation, KDM5B typically represses transcription and has essential roles in cell cycle progression, differentiation, and stem cell renewal. It is overexpressed in multiple cancers, where it contributes to tumor initiation, progression, invasion, and metastasis. Its status as an epigenetic modifier and emerging cancer target has led to the development of experimental inhibitors as potential anticancer agents[1][5][7][9].
Inhibition of demethylase activity on H3K4me3/me2 marks leading to altered transcription and potential re-expression of tumor suppressor genes
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysine-specific histone demethylase 5B (KDM5B).